Curated wellness tips, expert insights, and medication guides — written for real life.
An FDA panel voted to let pharmacies compound BPC-157 and 5 other peptides — but nothing is legal yet. What the 2026 peptide vote means for your safety, costs, and options.
Read the article
Survodutide just posted up to 13.1% weight loss in adults with obesity and type 2 diabetes. What the new Phase 3 data means, how it compares to Zepbound, and what to do now.
Read the article
New 2026 data from The Menopause Society links hormone therapy to greater GLP-1 weight loss in women over 45. What the study shows, the caveats, and what it means for your plan.
Read the article
A new randomized trial finds adults who got structured support after stopping a GLP-1 regained about a third as much weight in 4 months as those without a plan. What it means for your treatment.
Read the article
If you get medications through telehealth, December 31, 2026 matters: the DEA rules allowing controlled prescriptions online are set to expire. What changes, what doesn't, and how to prepare.
Read the article
The new VA/DoD obesity guideline gives semaglutide and tirzepatide its strongest recommendation for weight loss and maintenance, and advises against stopping once they work. What patients should know.
Read the article